Aroa Biosurgery’s Symphony Trial Hits Key Endpoint in Diabetic Foot Ulcers

Aroa Biosurgery Ltd ( (AU:ARX) ) has issued an update.

Aroa Biosurgery has completed a multi-centre randomised controlled trial of its Symphony skin substitute in patients with chronic Wagner grade 1 and 2 diabetic foot ulcers, comparing the product to standard care over a 12-week period. Preliminary results indicate the study met its primary endpoint, with more ulcers healing under Symphony than standard treatment, supporting the product’s safety and performance profile.

The company expects that full analysis and publication of the data will strengthen Symphony’s clinical-evidence base and help drive adoption in chronic, complex wounds, including diabetic foot and venous leg ulcers. Aroa also anticipates the results will help meet stringent clinical requirements for future U.S. reimbursement, potentially improving market access and reinforcing its competitive position in advanced wound care.

The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.58 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

More about Aroa Biosurgery Ltd

Aroa Biosurgery is a New Zealand–based soft-tissue regeneration company that develops, manufactures and sells medical and surgical products for complex wound healing and soft tissue reconstruction. Its products are built on the proprietary AROA ECM bioscaffold technology derived from ovine forestomach and are distributed globally, with a key focus on the U.S. market through a direct sales force and partner TELA Bio Inc.

Average Trading Volume: 120,787

Technical Sentiment Signal: Sell

Current Market Cap: A$196.9M

For detailed information about ARX stock, go to TipRanks’ Stock Analysis page.